Jiajun Zhang1, Sheng Wang1, Feng Han1, Jian Li1, Lan Yu2, Ping Zhou3, Zhijun Chen1, Sheng Xue1, Changyuan Dai1, Qingwen Li4. 1. Department of Urology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233030, China. 2. Department of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233030, China. 3. Department of Medical Examination of Bengbu Medical College, Bengbu, Anhui 233030, China. 4. Department of Urology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233030, China. Electronic address: 13865059474@163.com.
Abstract
AIM: To investigate the clinical significance of microRNA-542-3p (miR-542-3p) and its target gene survivin in human bladder cancer, and to determine their functions in malignant phenotypes of this disease. METHODS: Expression levels of miR-542-3p and survivin mRNA in bladder cancer and adjacent normal tissues were detected by quantitative RT-PCR. Cell proliferation and cell cycle were assessed by cell viability assay, flow cytometry and colony formation assay based on two human bladder cancer cell lines. RESULTS: MiR-542-3p expression was downregulated, while survivin mRNA expression was upregulated in bladder cancer tissues, compared to adjacent normal tissues (both P<0.001). Importantly, the expression level of miR-542-3p in bladder cancer tissues was negatively correlated with that of survivin mRNA. MiR-542-3p-low and/or survivin-high expression were all significantly associated with tumor stage (all P<0.05) and tumor recurrence (all P<0.05) of patients with bladder cancer. Moreover, the enforced expression of miR-542-3p remarkably inhibited cell proliferation by inducing G1 phase arrest in both T24 and J82 cells, and decreased the expression level of survivin protein. In contrast, the knock-down of miR-542-3p dramatically promoted the proliferation of bladder cancer cells by accelerating the progression of cell cycle and increased the expression level of survivin protein. CONCLUSION: MiR-542-3p and its target gene survivin may play crucial roles in the aggressive progression of human bladder cancer. More interestingly, miR-542-3p may function as a tumor suppressor and inhibit the proliferation of bladder cancer cells, implying that miR-542-3p-survivin signal axis might be a novel therapeutic target of this disease.
AIM: To investigate the clinical significance of microRNA-542-3p (miR-542-3p) and its target gene survivin in humanbladder cancer, and to determine their functions in malignant phenotypes of this disease. METHODS: Expression levels of miR-542-3p and survivin mRNA in bladder cancer and adjacent normal tissues were detected by quantitative RT-PCR. Cell proliferation and cell cycle were assessed by cell viability assay, flow cytometry and colony formation assay based on two humanbladder cancer cell lines. RESULTS: MiR-542-3p expression was downregulated, while survivin mRNA expression was upregulated in bladder cancer tissues, compared to adjacent normal tissues (both P<0.001). Importantly, the expression level of miR-542-3p in bladder cancer tissues was negatively correlated with that of survivin mRNA. MiR-542-3p-low and/or survivin-high expression were all significantly associated with tumor stage (all P<0.05) and tumor recurrence (all P<0.05) of patients with bladder cancer. Moreover, the enforced expression of miR-542-3p remarkably inhibited cell proliferation by inducing G1 phase arrest in both T24 and J82 cells, and decreased the expression level of survivin protein. In contrast, the knock-down of miR-542-3p dramatically promoted the proliferation of bladder cancer cells by accelerating the progression of cell cycle and increased the expression level of survivin protein. CONCLUSION: MiR-542-3p and its target gene survivin may play crucial roles in the aggressive progression of humanbladder cancer. More interestingly, miR-542-3p may function as a tumor suppressor and inhibit the proliferation of bladder cancer cells, implying that miR-542-3p-survivin signal axis might be a novel therapeutic target of this disease.
Authors: Rong Wang; Yuki Kang; Christiane V Löhr; Kay A Fischer; C Samuel Bradford; Gavin Johnson; Wan Mohaiza Dashwood; David E Williams; Emily Ho; Roderick H Dashwood Journal: Cancer Lett Date: 2016-08-15 Impact factor: 8.679
Authors: Milena Rizzo; Gabriele Berti; Francesco Russo; Sofia Fazio; Monica Evangelista; Romina D'Aurizio; Marco Pellegrini; Giuseppe Rainaldi Journal: J Cancer Date: 2017-08-22 Impact factor: 4.207